Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp PROF


Primary Symbol: T.PRN

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Post by MrMugsyon Mar 03, 2022 8:07pm
294 Views
Post# 34481395

Quarterly Conference Call

Quarterly Conference CallSounded promising but reoccurring revenue was only at $1M.
Would like to think the worst is over but it's going to take time.

Question is ... did we bottom out and are we heading the other direction now ?

I think they said they had 40 signed agreements.
Akumin is stalled but it has good future potential with their hospital base.
Paragon is new and coming on with its first location.
Pay per operation is now up to $8000.
Positive about getting a fair share of the overall market future market.
Various studies could be the catalyst for growth.

--------

Something like that. 
Lots to take in if you haven't listened to it yet. 


--------


<< Previous
Bullboard Posts
Next >>